FIFTH YEAR PHARM. D: SUMMER - 2018 SUBJECT: CLINICAL PHARMACOKINETICS AND PHARMACOTHERAPEUTIC DRUG MONITORING

Time : 10.00 AM to 01.00 PM Day : Tuesday Max. Marks: 70 Date : 10/04/2018 S-2018-4047 N. B.: Q. No. 1 and Q. No. 5 are COMPULSORY. Out of remaining Any TWO 1) questions from Section - I and Any TWO questions from Section - II. Both the sections should be written in the **SEPARATE** answer book. 2) Figures to the right indicate FULL marks. 3) **SECTION - I** Answer **Any FOUR** of the following: (08)Q.1 a) Name two hepatic enzyme inducers. i)) Give examples of drug for which TDM is not required. iii) Give formula for calculation of pediatric doses. iv) Define clinical pharmacokinetics. v) Define volume of distribution. vi) What is therapeutic index? b) Describe pharmacokinetic drug interactions with examples. (03)Define therapeutic drug monitoring (TDM). Explain the indications and (12) **Q.2** applications of TDM in details. Describe the intravenous to oral dosing conversion. (07)Q.3 a) Describe the inhibition of biliary excretion and its effect on pharmacokinetics. (05)**Q.4** Write short notes on **Any THREE** of the following: (12)TDM of lithium a) Methotrexate b) c) Nomograms Drug dosing in obese patients d)

SECTION - II

Q.5	A)	Answer Any FOUR of the following:	(08)
	i))	How do you adjust dose of a drug in a renal impairment with a constant dosing interval.	
	ii)	Calculate creatinine clearance in an 85 year old female weighing 190 lbs, with	
	iii)	serum creatinine concentration of 1.5 mg/100ml. Give examples of hepatic makers and their importance.	
	iv)	Define genetic polymorphism and give examples.	
	v)	Define pharmacogenetics.	
	vi)	Explain the intrinsic clearance of drug.	
	B)	Describe genetic polymorphism in CYP2D6.	(03)
Q.6		What is population pharmacokinetic data? Explain in detail the methods adopted in analysis of such data.	(12)
Q. 7	a)	What is Bayesian theory? Explain with suitable example.	(07)
	b)	What is extracorporeal removal of drugs? Explain.	(05)
Q.8		Write short notes on Any THREE of the following:	(12)
	a)	Effect of hepatic diseases on pharmacokinetics	
	b)	Role of genetic polymorphism in drug metabolism	
	c)	Effect of renal and hepatic diseases on protein binding	
	d)	Methods of determining creatinine clearance in adults	
		* * * * *	